Design of Pharmacological & Phytochemical Screening of Herbal Drugs for Treatment of Dementia

Background: Dementia is a progressive neurodegenerative disorder characterized by deterioration in memory, cognition, learning ability, and behavioral functions, leading to significant disability among the elderly population. Current pharmacological therapies, including acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, provide only symptomatic relief and are associated with limited efficacy and adverse effects. Consequently, medicinal plants have gained increasing attention as potential therapeutic agents because of their rich phytochemical composition and multitarget neuroprotective properties. Objective: The present study is designed to establish a comprehensive framework for the phytochemical characterization and pharmacological evaluation of selected medicinal plants with potential anti-dementia activity. Methods: The proposed study includes authentication and extraction of selected herbal drugs followed by preliminary and advanced phytochemical screening using standard qualitative tests, thin-layer chromatography (TLC), high-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC), gas chromatography–mass spectrometry (GC–MS), liquid chromatography–mass spectrometry (LC–MS/MS), Fourier-transform infrared spectroscopy (FTIR), and ultraviolet-visible (UV–Visible) spectroscopy for the identification and characterization of bioactive constituents. Pharmacological screening is designed to include in vitro acetylcholinesterase and butyrylcholinesterase inhibition assays, antioxidant assays (DPPH, ABTS, and FRAP), β-amyloid aggregation inhibition studies, and neuroprotection assays using neuronal cell lines. The in vivo evaluation is proposed using validated animal models of cognitive impairment, including scopolamine-induced amnesia, with behavioral assessments performed using the Morris water maze, Y-maze, radial arm maze, elevated plus maze, and passive avoidance test. Biochemical estimation of oxidative stress markers, inflammatory cytokines, acetylcholinesterase activity, neurotransmitter levels, and histopathological examination of brain tissues are included to elucidate the mechanisms underlying neuroprotection. Expected Outcomes: The integrated phytochemical and pharmacological screening strategy is expected to identify bioactive phytoconstituents with antioxidant, anti-inflammatory, anti-amyloidogenic, cholinesterase inhibitory, and neuroprotective activities. The study design will facilitate the standardization and scientific validation of herbal drugs and provide mechanistic evidence supporting their potential application in the prevention and management of dementia. Conclusion: This comprehensive experimental design provides a systematic approach for evaluating medicinal plants as potential anti-dementia agents. The findings generated through this protocol are expected to contribute to the discovery of safe, effective, and evidence-based phytopharmaceuticals for the treatment of dementia and may support future preclinical and clinical investigations.